Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy
Publication year
2016Source
Clinical Imaging, 40, 4, (2016), pp. 745-50ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Medical Imaging
Urology
Pathology
Journal title
Clinical Imaging
Volume
vol. 40
Issue
iss. 4
Page start
p. 745
Page end
p. 50
Subject
Radboudumc 0: Other Research RIHS: Radboud Institute for Health Sciences; Radboudumc 15: Urological cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 15: Urological cancers RIMLS: Radboud Institute for Molecular Life SciencesAbstract
OBJECTIVES: To determine transrectal ultrasound (TRUS) visibility of magnetic resonance (MR) lesions. METHODS: Data from 34 patients with 56 MR lesions and prostatectomy were used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to Prostate Imaging-Reporting and Data System (PIRADS) and Gleason scores. RESULTS: TRUS visibility occurred in 43% of all MR lesions and in 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS-visible lesions had a Gleason 4 or 5 component. CONCLUSIONS: Almost half of the MR lesions were visible on TRUS. TRUS-visible lesions were more aggressive than TRUS-invisible lesions.
This item appears in the following Collection(s)
- Academic publications [238441]
- Electronic publications [122525]
- Faculty of Medical Sciences [90373]
- Open Access publications [97520]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.